Biotest AG
BiotechBiotest AG is a biotechnology company focused on Infectious Disease, Immunology. Key products include YIMMUGO.
Biotest AG at a Glance
- Fast trial execution (29 months median completion)
Biotest AG's Key Drugs
Biotest AG's core commercial portfolio centers on YIMMUGO, spanning Infectious Disease and Immunology — its most strategically important drugs approved in the last 15 years.
Biotest AG's Recent FDA Approvals
New NDA/BLA approvals for Biotest AG over the last two years — novel drugs only, excluding generics and label supplements.
Biotest AG's Therapeutic Areas
Biotest AG's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Immunology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Biotest AG's Top Competitors
Biotest AG's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Biotest AG Pipeline Snapshot
Biotest AG has 8 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 4 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • YIMMUGO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 5/8 completed
- • Speed: 29 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-06-13
- Latest
- 2024-06-13
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges